Your session is about to expire
← Back to Search
Pembrolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial is testing pembrolizumab given with paclitaxel, carboplatin, and radiation therapy to treat stage II-IIIB non-small cell lung cancer to learn the best dose and way to give it, and to find out what side effects it causes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function, measured by creatinine or GFR, is within the normal range.I agree to use birth control during and for 4 months after the study.I have another cancer, but it's either being treated or not worsening, except for certain skin cancers or cervical cancer.You are allergic to pembrolizumab or any of the ingredients in it.I have not received a live vaccine in the last 30 days.My lung cancer is at a stage that cannot be surgically removed and requires combined chemotherapy and radiation.I am using two birth control methods or am not having sex to join this study.My lung function test shows I can breathe out at least 1.0 L or 40% of what's expected.I have fully recovered from any major surgery before starting treatment.I have active hepatitis B or C.My pleural effusion cannot be managed despite treatments.I have an immune system disorder or have been on steroids or other immune-weakening medicines recently.I have been diagnosed with HIV.I agree to provide a recent biopsy sample or, if not possible, an older sample with approval.My lung cancer type was confirmed not just by sputum tests.I am fully active or restricted in physically strenuous activity but can do light work.My blood clotting time is normal or managed with medication.I haven't had cancer treatment with a monoclonal antibody in the last 4 weeks or have recovered from its side effects.My blood clotting time is normal or managed if I'm on blood thinners.I do not have active brain metastases or carcinomatous meningitis.I do not have any other ongoing cancers.My liver function tests are within the required range.I haven't had cancer treatment in the last 2 weeks or have recovered from its side effects.My hemoglobin level is above 9 g/dL without needing transfusions or EPO recently.You have had an allergic reaction or sensitivity to any part of the treatment in the past.I have been treated with drugs targeting PD-1 or PD-L1 before.I am currently being treated for an infection.I have or had lung inflammation not caused by an infection.I have an active TB infection.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.I have mild to moderate nerve damage.
- Group 1: Treatment (paclitaxel, carboplatin, radiation, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are involved in this experiment?
"As of now, this medical trial is not accepting participants. Initially posted on April 11th 2016 and revised on April 28th 2022; if you are searching for alternate clinical studies, there are currently 1909 trials recruiting non-small cell lung carcinoma patients and 1990 research projects with Pembrolizumab seeking enrolment."
Can you enumerate any previous studies conducted with Pembrolizumab?
"Currently, there are 1990 research studies concerning the drug pembrolizumab. Of these trials, 413 are in their third phase of clinical testing and administered at 91501 locations around Shanghai."
In what clinical applications is Pembrolizumab most frequently utilized?
"Pembrolizumab is commonly prescribed to alleviate the symptoms of malignant neoplasms. It may also be recommended for individuals with unresectable melanoma, microsatellite instability high, and high risk of recurrence."
Has Pembrolizumab received regulatory sanction from the FDA?
"The safety of Pembrolizumab is tentatively rated at 1, as the Phase 1 trial provides limited data regarding its efficacy and potential dangers."
Are there any open enrollment opportunities for this experiment?
"According to clinicaltrials.gov, this particular research initiative is not recruiting and has been last updated on April 28th 2022 since its inception in 2016. Nevertheless, there are 3899 other trials actively searching for volunteers at present."
Share this study with friends
Copy Link
Messenger